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etanercept. For the combined ACR & PASI scores, the NNT
ranges were 2.3 to 7.0 for inﬂiximab and 2.9 to 33.3 for etan-
ercept. Using average wholesale price minus 15% (AWP -15%),
the cost per successful outcome based on the ACR score ranged
from $54,235 to $82,435 for inﬂiximab and from $43,000 to
$198,860 for etanercept. For PASI scores, the cost per success-
ful outcome ranged from $30,900 to $53,390 for inﬂiximab and
from $54,860 to $530,280 for etanercept. For the combined
ACR & PASI scores, the cost per successful outcome ranged from
$46,280 to $144,220 for inﬂiximab and from $46,790 to
$530,280 for etanercept. CONLCUSIONS: This Excel based CE
model enables payers to perform CE analyses for anti-TNF
agents used in the treatment of psoriatic arthritis, utilizing plan-
speciﬁc cost and utilization data.
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OBJECTIVES: This prospective, observational, study evaluated
the drug utilization patterns and cost of treatment of patients
treated for rheumatoid arthritis at a government institution
versus a private institution in Kerala, India. METHODS:
Patients with a diagnosis of rheumatoid arthritis were enrolled
into the study and were followed for a period of six months.
Data regarding demographics, clinical outcome, laboratory
results, drug utilizations, and cost was collected. The cost of drug
therapy for each patient was calculated utilizing the Current
Index of Medical Specialties 2004. Nominal data was analyzed
using Chi square and Fisher’s exact test and logistic regression
univariate analysis was conducted to determine the association
between disease improvement and treatment factors. RESULTS:
One hundred thirty-one patients were enrolled in the study, 96
at the government institution and 35 at the private institution.
The mean age was 42.61 and 80% of the patients were female.
The most frequently utilized DMARD was methotrexate, 66%
for the government institution and 80% for the private institu-
tion. The most common DMARD combination therapy was
methotrexate plus hydroxycholoroquine (62.96%). Compliance
was 68.75% in the government patients versus 94.28% in the
private patients (P = 0.003). Logistic regression results indicated
that increased WBC (p = 0.032), ESR (0.003), and COX-2 
usage (p = 0.039) was associated with poorer clinical outcome,
while methotrexate use (p = 0.029) and physiotherapy (p =
0.041) was associated with improved outcome. The clinical
outcome was not signiﬁcantly associated with the site of care.
The average cost of care was Rs. 420.13 per month at the 
government institution versus Rs. 713.14 per month at the
private institution, and 16.1% of the total noncompliance was
due to ﬁnancial constraints. CONCLUSION: The treatment of
rheumatoid arthritis is best managed with a protocol that
includes methotrexate. While ﬁnancial constraints affect the
compliance rate, the site of care did not have any impact on 
clinical outcome.
ARTHRITIS—Health Care Use and Policy Studies
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OBJECTIVES: Cyclo-oxygenase (COX)-2 inhibitor rofecoxib
and valdecoxib were withdrawn from the market because of
their association with heart problems. There is a lack of infor-
mation on the impacts of COX-2 withdrawal on the utilization
of related drug classes. The objective is to evaluate to what extent
prescriptions and expenditures of non-selective non-steroidal
anti-inﬂammatory drugs (NSAIDs) and proton pump inhibitors
(PPIs) changed after the removal of two COX-2 drugs.
METHODS: Prescription records from January 1, 2004 through
November 30, 2005 were obtained from pharmacy claims data-
base in a pharmacy beneﬁt management (PBM) organization.
Clients continuously enrolled in the PBM but not enrolled in
COX-2, PPI, or Prilosec OTC Step Care programs during the
study period were included. Number of prescriptions per thou-
sand eligible members per month, per member per month
(PMPM) total costs for non-selective NSAIDs and PPIs were cal-
culated and compared between the pre withdrawal (January 1,
2004 through September 30, 2004) and the post withdrawal
(May 1, 2005 through November 30, 2005). RESULTS: This
study included 536,569 patients. After the withdrawal of the two
COX-2 inhibitors, the average non-selective NSAID prescrip-
tions per thousand eligible members per month and PMPM total
costs increased by 37.72% (from 13.94 to 19.20) and 75.56%
(from $0.52 to $0.91). PPI prescriptions and PMPM total costs
increased by 7.21% (from 25.73 to 27.58) and 12.32% (from
$4.38 to $4.92). In contrast, the average prescriptions and
PMPM total costs for COX-2 inhibitors dropped by 70.99%
(from 16.52 to 4.79) and 66.16% (from $2.07 to $0.70). CON-
CLUSIONS: After the withdrawal of COX-2 inhibitor rofecoxib
and valdecoxib, there has been a large increase in non-selective
NSAID prescriptions and only slight increase of PPIs. Given the
safety concerns with the NSAIDs, further studies are warranted
regarding the health outcomes associated with the increased use
of non-selective NSAIDs.
ARTHRITIS—Methods and Concepts
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OBJECTIVES: Different pain thresholds were investigated, using
the WOMAC Pain Scale (WOMAC-P) to determine if they could
differentiate between treatment groups (hylan G-F 20 vs appro-
priate care) at low and very low levels of state-attainment in
patients with knee osteoarthritis. A method, termed the BLISS
(Bellamy et al Low Intensity Symptom State-attainment) Index,
for analyzing Osteoarthritis (OA) knee clinical trials data, was
proposed. METHODS: Five analyses were performed: time to
ﬁrst BLISS day, BLISS days over 12 months, patients with a
BLISS response at month 12, patients with a BLISS response at
any time, and number of BLISS periods over 12 months. For each
analysis, ﬁve levels of WOMAC-P were examined: ≤5 Normal-
ized Units (NU), ≤10, ≤15, ≤20 and ≤25 (higher = more pain).
RESULTS: More patients in the hylan G-F 20 group achieved
BLISS states in all ﬁve analyses. These differences were statisti-
cally signiﬁcant for all pain threshold levels except ≤5NU. CON-
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CLUSIONS: Five methods of measuring BLISS attainment using
four pre-speciﬁed threshold levels of pain were able to statisti-
cally discriminate between treatment groups. This method may
potentially provide an approach, to deﬁning which patients not
only improve but also achieve a good state of health, at low and
very low levels of pain intensity. BLISS -10 is a therapeutically
attainable very low symptom state at which clinically important,
statistically signiﬁcant between group differences are detectable,
and therefore may provide a benchmark against which thera-
peutic interventions can be assessed. However, the value to
patients, of this and other low and very low intensity pain states,
requires further elaboration.
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OBJECTIVE: To evaluate osteoarthritis (OA) patients’ ability to
state valid preferences for tradeoffs between treatment-related
serious adverse events (SAEs) and speciﬁed treatment beneﬁts.
METHODS: A web-enabled, choice-format, conjoint or stated-
preference survey was developed to elicit OA patients’ willing-
ness to accept tradeoffs between SAE probabilities and treatment
efﬁcacy. The treatment attributes included in the tradeoff tasks
employed graphical elements indicating pain and stiffness sever-
ity on a continuous visual analog scale, mild-to-moderate gas-
trointestinal (GI) symptoms measured by type of intervention
required, and bleeding ulcer, heart infarct, and stroke probabil-
ities shown numerically and visually on a 100-square grid. The
instrument was pretested with a convenience sample of 8 OA
patients and administered to a sample of OA patients in a large-
scale pilot survey. Random-parameter logit estimates were used
to calculate maximum acceptable 10-year MAR various levels of
clinical beneﬁt. RESULTS: A total of 156 patients completed the
pilot survey. Only 4% of subjects failed the irrational-choice and
14% failed the cross-question monotonicity internal validity
tests. Patients discriminated successfully among pain and SAE
risk levels. Mild-to-moderate gastrointestinal side effects had no
signiﬁcant effect on treatment choices. Pain control was about
twice as important as control of stiffness, and stroke likelihood
was the most important SAE risk. Maximum acceptable risk
(MAR) increased as expected with greater therapeutic beneﬁts
and decreased inversely with the importance of SAE risks. Mean
MAR for a maximal improvement from moderate daily symp-
toms to full symptom control was signiﬁcantly greater than 0.05
for ulcer, infarct, and stroke (p < 0.001 for all). CONCLU-
SIONS: All medical interventions carry risks of adverse outcomes
that must be evaluated against their clinical beneﬁts. OA patients
in this pilot study indicated they were willing to accept SAE risks
in excess of clinical levels for sufﬁciently large improvements in
symptom control.
ARTHRITIS—Patient Reported Outcomes
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OBJECTIVES: To characterize health related quality of life
(HRQoL) among persons with and without arthritis or chronic
joint symptoms (CJS). METHODS: Data obtained from the
2004 Behavioral Risk Factor Surveillance Survey (BRFSS), an
ongoing, state-based, random-digit-dialed telephone survey of
non-institutionalized persons aged >/= 18 years conducted in all
states. Data from nine states (54,116 participants) were included
in the analysis as these states had included both components of
arthritis and HRQoL measures (mental, physical, and poor
health) in the 2004 survey. Multiple linear regression analyses
were used to examine the associations between selected sociode-
mographic and behavioral determinants and HRQoL among
participants with arthritis or CJS. RESULTS: Of the respondents
32% had been diagnosed with some form of arthritis by a health
care professional and 46% had joint pain in the past 30 days.
The respondents with arthritis had a mean of 6.75 physically and
4.58 mentally unhealthy days and 6.41 poor health days during
the past 30 days compared with 2.29, 3.14, and 2.76 among
those without arthritis. Only 36.9% of participants with arthri-
tis reported very good general health versus 60.9% of respon-
dents without arthritis (p = 0.000). For each unit of age increase
of participants with arthritis there was an increase in physical,
mental, and poor unhealthy days. Based on WHO’s classiﬁcation
of obesity, the respondents with arthritis included approximately
30.9% normal weight, 37.3% overweight, 27% obese, and
4.7% severely obese respondents. Regression analysis indicated
that severely obese, obese, and over weight experienced more
unhealthy physical and poor days than respondents with normal
weight. Active men and women were less likely to report poor
unhealthy days compared with those who did not exercise in the
past 30 days. CONCLUSIONS: Findings indicate that persons
with arthritis or CJS experience a decrease in HRQOL as com-
pared to those without arthritis.
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OBJECTIVES: Osteoarthritis is prevalent and debilitating
disease that affects nearly 21 million Americans. For clinicians
to assess the impact of treatment strategies require reliable, valid
and interpretable measures. We conducted a systematic review
of WOMAC which is a disease speciﬁc instrument measuring
HRQL of patients with osteoarthritis. The review considered the
evaluative, discriminative properties and interpretability of the
instrument. The last systematic review was published in 2001.
METHODS: A structured literature review was performed to
identify evidence related to measurement properties (reliability,
internal consistency, responsiveness, and interpretability) of
WOMAC using two databases (MEDLINE and HealthSTAR)
from 1982 to December 2005. We included randomized con-
trolled trials and observational studies. RESULTS: Of 307 and
137 papers, 14 met the inclusion criterion. Discriminative: We
found high reliability (correlation coefﬁcients) for domains of
pain and physical function (>0.7), compared to the stiffness
domain (>0.6). All domains had generally high construct valid-
ity in differentiating among patients with better/worse HRQL.
The internal consistency (Cronbach’s alpha) was high (>0.8).
WOMAC generally had high construct validity. Responsiveness
varied by domain and by intervention. WOMAC was more
responsive in patients who underwent total hip or knee arthro-
plasty compared to other interventions. We found that the phys-
ical function domain was more responsive than other domains
